Experimental arthritis induced by a clinical Mycoplasma fermentans isolate

BACKGROUND: Mycoplasma fermentans has been associated with rheumatoid arthritis. Recently, it was detected in the joints and blood of patients with rheumatoid arthritis, but it is not clear yet how the bacteria enter the body and reach the joints. The purpose of this study was to determine the ability of M. fermentans to induce experimental arthritis in rabbits following inoculation of the bacteria in the trachea and knee joints. METHODS: P-140 and PG-18 strains were each injected in the knee joints of 14 rabbits in order to evaluate and compare their arthritogenicity. P-140 was also injected in the trachea of 14 rabbits in order to test the ability of the bacteria to reach the joints and induce arthritis. RESULTS: M. fermentans produced an acute arthritis in rabbits. Joint swelling appeared first in rabbits injected with P-140, which caused a more severe arthritis than PG-18. Both strains were able to migrate to the uninoculated knee joints and they were detected viable in the joints all along the duration of the experiment. Changes in the synovial tissue were more severe by the end of the experiment and characterized by the infiltration of neutrophils and substitution of adipose tissue by connective tissue. Rabbits intracheally injected with P-140 showed induced arthritis and the bacteria could be isolated from lungs, blood, heart, kidney, spleen, brain and joints. CONCLUSION: M. fermentans induced arthritis regardless of the inoculation route. These findings may help explain why mycoplasmas are commonly isolated from the joints of rheumatic patients

Effectiveness of an intervention for improving drug prescription in primary care patients with multimorbidity and polypharmacy:Study protocol of a cluster randomized clinical trial (Multi-PAP project)

This study was funded by the Fondo de Investigaciones Sanitarias ISCIII (Grant Numbers PI15/00276, PI15/00572, PI15/00996), REDISSEC (Project Numbers RD12/0001/0012, RD16/0001/0005), and the European Regional Development Fund ("A way to build Europe").Background: Multimorbidity is associated with negative effects both on people's health and on healthcare systems. A key problem linked to multimorbidity is polypharmacy, which in turn is associated with increased risk of partly preventable adverse effects, including mortality. The Ariadne principles describe a model of care based on a thorough assessment of diseases, treatments (and potential interactions), clinical status, context and preferences of patients with multimorbidity, with the aim of prioritizing and sharing realistic treatment goals that guide an individualized management. The aim of this study is to evaluate the effectiveness of a complex intervention that implements the Ariadne principles in a population of young-old patients with multimorbidity and polypharmacy. The intervention seeks to improve the appropriateness of prescribing in primary care (PC), as measured by the medication appropriateness index (MAI) score at 6 and 12months, as compared with usual care. Methods/Design: Design:pragmatic cluster randomized clinical trial. Unit of randomization: family physician (FP). Unit of analysis: patient. Scope: PC health centres in three autonomous communities: Aragon, Madrid, and Andalusia (Spain). Population: patients aged 65-74years with multimorbidity (≥3 chronic diseases) and polypharmacy (≥5 drugs prescribed in ≥3months). Sample size: n=400 (200 per study arm). Intervention: complex intervention based on the implementation of the Ariadne principles with two components: (1) FP training and (2) FP-patient interview. Outcomes: MAI score, health services use, quality of life (Euroqol 5D-5L), pharmacotherapy and adherence to treatment (Morisky-Green, Haynes-Sackett), and clinical and socio-demographic variables. Statistical analysis: primary outcome is the difference in MAI score between T0 and T1 and corresponding 95% confidence interval. Adjustment for confounding factors will be performed by multilevel analysis. All analyses will be carried out in accordance with the intention-to-treat principle. Discussion: It is essential to provide evidence concerning interventions on PC patients with polypharmacy and multimorbidity, conducted in the context of routine clinical practice, and involving young-old patients with significant potential for preventing negative health outcomes. Trial registration: Clinicaltrials.gov, NCT02866799Publisher PDFPeer reviewe

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants

Background Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. Methods We used data from 1990 to 2019 on people aged 30–79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. Findings The number of people aged 30–79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306–359) million women and 317 (292–344) million men in 1990 to 626 (584–668) million women and 652 (604–698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55–62) of women and 49% (46–52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43–51) of women and 38% (35–41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20–27) for women and 18% (16–21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. Interpretation Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings

Distribución heterogénea de la prevalencia de anticuerpos contra Trypanosoma cruzi en donadores de sangre en Puebla, México

Objetivo. Identificar la seroprevalencia de anticuerpos anti Trypanosoma cruzi (Ac anti-T. cruzi) en donadores de sangre que habitan en ámbito rural y suburbano, así como las regiones del estado de mayor riesgo y factores asociados. Material y métodos. Estudio transversal realizado de enero a diciembre de 2003. Se analizaron 2 489 donadores de sangre reclutados en 10 puestos de sangrado del Instituto Mexicano del Seguro Social (IMSS) distribuidos en las siete regiones económicas del estado de Puebla, México. Se determinó la seroprevalencia mediante las pruebas serológicas obligatorias del panel viral y, además, para T. cruzi, región de reclutamiento y de origen de los donadores. Resultados. La seroprevalencia de Ac anti-T. cruzi fue de 1.24% (31/2 489) comparable con la obtenida para el virus de la hepatitis C (1.5%) y por arriba de la del virus de la inmunodeficiencia humana (0.4%) y del antígeno de superficie del virus de la hepatitis B (0.3%). Las regiones de Tehuacán- Sierra Negra y Mixteca fueron las de mayor riesgo con seroprevalencias, por el origen del donador, de 2.6% para T. cruzi, mientras que en los originarios de las regiones Sierra nororiental y Angelópolis no se detectaron casos positivos. Se observó asociación entre ser seropositivo y mayor de 40 años y ser originario de las regiones de Tehuacán-Sierra Negra y Mixteca. Conclusiones. La distribución de seroprevalencia a T. cruzi es heterogénea, oscila desde 0% hasta 2.6%, y se reconoce a Tehuacán-Sierra Negra y Mixteca como las regiones de mayor riesgo

Distribución heterogénea de la prevalencia de anticuerpos contra Trypanosoma cruzi en donadores de sangre en Puebla, México Heterogeneous distribution of the prevalence of anti-Trypanosoma cruzi antibodies among blood donors in the State of Puebla, Mexico

OBJETIVO: Identificar la seroprevalencia de anticuerpos anti Trypanosoma cruzi (Ac anti-T. cruzi) en donadores de sangre que habitan en ámbito rural y suburbano, así como las regiones del estado de mayor riesgo y factores asociados. MATERIAL Y MÉTODOS: Estudio transversal realizado de enero a diciembre de 2003. Se analizaron 2 489 donadores de sangre reclutados en 10 puestos de sangrado del Instituto Mexicano del Seguro Social (IMSS) distribuidos en las siete regiones económicas del estado de Puebla, México. Se determinó la seroprevalencia mediante las pruebas serológicas obligatorias del panel viral y, además, para T. cruzi, región de reclutamiento y de origen de los donadores. RESULTADOS: La seroprevalencia de Ac anti-T. cruzi fue de 1.24% (31/2 489) comparable con la obtenida para el virus de la hepatitis C (1.5%) y por arriba de la del virus de la inmunodeficiencia humana (0.4%) y del antígeno de superficie del virus de la hepatitis B (0.3%). Las regiones de Tehuacán-Sierra Negra y Mixteca fueron las de mayor riesgo con seroprevalencias, por el origen del donador, de 2.6% para T. cruzi, mientras que en los originarios de las regiones Sierra nororiental y Angelópolis no se detectaron casos positivos. Se observó asociación entre ser seropositivo y mayor de 40 años y ser originario de las regiones de Tehuacán-Sierra Negra y Mixteca. CONCLUSIONES: La distribución de seroprevalencia a T. cruzi es heterogénea, oscila desde 0% hasta 2.6%, y se reconoce a Tehuacán-Sierra Negra y Mixteca como las regiones de mayor riesgo.OBJECTIVE: To determine the seroprevalence and associated factors, of antibodies against Trypanosoma cruzi (T. cruzi Ab) among blood donors living in rural and suburban areas and risk regions. MATERIAL AND METHODS: A cross-sectional study was conducted from January to December 2003, in 2489 blood donors of seven regions of Puebla, who were evaluated for mandatory viral and T. cruzi serological tests using validated procedures RESULTS: The seroprevalence for T. cruzi Ab was 1.24% (31/2489), similar to hepatitis C (HVC) (1.5%) and higher than human immunodeficiency virus (HIV) (0.4%) and hepatitis B (HVB) (0.3%). The highest seroprevalences were observed in the regions of Tehuacan-Sierra Negra and Mixteca, up to 2.6%, while in Sierra nororiental and Angelopolis no positive blood donors were identified. A positive association was observed between seropositivity and being older than forty years and being born and raised in Tehuacan-Sierra Negra and Mixteca. CONCLUSIONS: T.cruzi seroprevalence distribution is heterogeneous, from 0% to 2.6%, with higher seroprevalences in the regions of Tehuacan-Sierra Negra and Mixteca

Antimicrobial Susceptibility of Bacteria and Yeasts Isolated from the Milk of Dairy Cattle Presenting with Subclinical Mastitis in Puebla, Mexico

"This study was designed to identify the bacteria and yeasts from the milk samples of dairy cattle presenting with subclinical mastitis and evaluate their antimicrobial susceptibility. We collected a total of 52 milk samples from cows across three farms in San Salvador El Seco (Puebla, Mexico). Microbial isolation was performed using microbiological techniques followed by taxonomic identification of bacteria and yeasts. Antimicrobial susceptibility was evaluated using the guidelines provided by the Clinical Laboratory Standard Institute (CLSI). 1 We identified three genera and six species of yeasts including Candida glabrata, C. krusei, C. lipolytica, Cryptococcus laurentii, Rhodotorula rubra, and R. glutinis and five species of bacteria, including Staphylococcus saprophyticus, S. aureus, S. hominis, S. epidermidis, and Streptococcus disgalactiae. All of the yeast strains were sensitive to amphotericin B; 1/23 (4.3%) were resistant to ketoconazole and nystatin, 10/23 (43%) were resistant to fluconazole, and 13/23 (53%) were resistant to 5-fluorocytosine. The dominant genus isolated was Candida, with the most abundant groups being C glabrata and C. krusei. Resistance to 5-fluorocytosine was observed in all yeasts except C. lipolytica, while both S. aureus and S. epidermidis were resistant to oxacillin and dicloxacillin. S. hominis was resistant to gentamicin"

La investigación formativa

Se ha realizado el tercer Encuentro Científico y Educativo de Experiencias Investigativas (ece2i), un espacio de investigación formativa de suma importancia para la comunidad académica de la UNIAJC, en cuanto en él se socializan los aportes realizados por estudiantes y docentes, producto de sus trabajos investigativos desarrollados al interior de los grupos y semilleros de la Institución. En este documento, que consolida la memoria académica del evento, da cuenta de la diversidad de trabajos y la pertinencia de ellos en el contexto inmediato. Definitivamente, este ejercicio de escritura es una muestra de cómo nuestros estudiantes y docentes se piensan la universidad desde su quehacer cotidiano y académico. Recae sobre cada uno de nosotros la responsabilidad de darle el impacto que realmente se merece esta publicación, donde docentes y estudiantes se han esforzado por resolver problemáticas puntuales que atienden necesidades concretas de nuestro entorno